Table 4 Odds ratios for baseline and time-varying predictors of adherence ≥ 90%.

Dosing schedule (prophylaxis group)

Three times a week

1

1

Daily

0.88 (0.66, 1.17) 0.38

0.85 (0.64, 1.11) 0.23

Study site

RCCH

1

1

TCH

1.25 (0.95, 1.67) 0.11

1.12 (0.82, 1.54) 0.46

Gender

Male

1

1

Female

1.17 (0.87, 1.57) 0.30

1.11 (0.82, 1.50) 0.51

Number of individuals in house

≤ 5

1

1

> 5

0.77 (0.57 1.02) 0.07

0.71 (0.54, 0.95) 0.02

Brick house

No

1

-

Yes

0.98 (0.73, 1.30) 0.87

Tap water in house

No

1

-

Yes

1.07 (0.80, 1.43) 0.64

Flush toilet in house

No

1

-

Yes

1.08 (0.82, 1.44) 0.57

Electricity in house

No

1

-

Yes

0.93 (0.61, 1.41) 0.74

Time-varying characteristics

Age at visit

< 1 year

1

1

1-4 years

0.77 (0.6, 0.98) 0.03

1.47 (0.91, 2.37) 0.11

> 4 years

1.40 (1.09, 1.80) 0.008

1.96 (1.16, 3.32) 0.012

Time on study at visit

< 1 year

1

1

≥ 1 year

0.82 (0.67, 1.01) 0.06

0.83 (0.66, 1.05) 0.12

CDC clinical

N or A

1

1

   stage at visit

B

1.11 (0.85, 1.46) 0.44

0.85 (0.54, 1.34) 0.48

C

0.86 (0.65, 1.14) 0.30

0.71 (0.43, 1.16) 0.17

CDC immune

1

1

1

   Stage at visit

2

0.94 (0.73, 1.20) 0.62

0.96 (0.69, 1.34) 0.83

3

1.02 (0.79, 1.32) 0.86

1.00 (0.70, 1.44) 0.99

Study drug at visit

Placebo

1

-

Isoniazid

1.02 (0.73, 1.43) 0.91

-

On HAART at visit

No

1

1

Yes

1.14 (0.89, 1.45) 0.30

1.08 (0.82, 1.43) 0.56